Sylvatica Biotech
Sylvatica Biotech is a privately held cryobiology R&D company developing supercooling and partial-freezing technologies to extend human organ and tissue preservation from hours to days, targeting transplant centers, drug discovery, and regenerative medicine applications.
- Company typePrivate
- Founded2015
- HeadquartersNorth Charleston, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Sylvatica Biotech does
Sylvatica Biotech Inc is a privately held, venture-backed cryobiology R&D company founded in 2015 and based in North Charleston, United States. Its core platform centers on subzero, non-frozen preservation of human organs and tissues — principally human livers — using proprietary supercooling (to -4°C without ice formation) and partial-freezing techniques that extend viable preservation time from hours to multiple days, with published evidence of transplantation survival after 4 days of supercooled preservation and a 5-fold extension of rat liver preservation via partial freezing.
The technology is supported by an unusually strong scientific footprint for a sub-10-person company: peer-reviewed publications in Nature Biotechnology (including a 2019 cover feature), Nature Medicine, Nature Communications, Nature Protocols, and PNAS; presentation at the White House Organ Summit, Harvard Organ Banking Summit, and STIR 2018; and earned media in MIT Technology Review, The Atlantic, The Economist, PNAS, and Scientific American. Funding partnerships with the NIH and the U.S. Department of Defense were established in 2019, with NIH Director Dr. Francis Collins publicly endorsing the work.
Sylvatica is pre-commercial. It has no disclosed revenue, no product distribution channels, and no publicly disclosed pricing; the company identifies three future customer segments — healthcare providers and transplant centers (primary), pharmaceutical and drug discovery buyers, and regenerative medicine developers — and is advancing its lead liver program through translational work toward eventual clinical, FDA-regulated commercialization. Cumulative disclosed funding is approximately $12.6M across six rounds between 2015 and 2021, including a $6.99M 2019 round and a 2021 round with Taihill Venture and Unpopular Ventures.
Sylvatica Biotech firmographics
Firmographics- Name
- Sylvatica Biotech
- Legal name
- Sylvatica Biotech Inc
- Website
- https://sylvaticabio.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Sylvatica Biotech is a privately held cryobiology R&D company developing supercooling and partial-freezing technologies to extend human organ and tissue preservation from hours to days, targeting transplant centers, drug discovery, and regenerative medicine applications.
- Ownership category
- akta.pro rank
Sylvatica Biotech industry classification
Industry- Product category
- Organ Preservation Technology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies (HLAAAJAN)
- akta.pro secondary industries
- Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats) (HLAGAIAJ), Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low) (HLAGAGAK)
Keywords
Where Sylvatica Biotech is headquartered
LocationHeadquarters
- HQ city
- North Charleston
- HQ country
- United States
- HQ region
- North America
Markets served
Sylvatica Biotech business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Marketing channels3 records
Sylvatica Biotech product offering
Product offeringCore offering
Sylvatica Biotech is a cryobanking R&D company developing proprietary supercooling and partial-freezing technologies to preserve human organs (notably livers) at subzero temperatures without ice formation, extending preservation from hours to days. The technology targets transplantation, drug discovery, and regenerative medicine applications. The company is pre-commercial and focused on advancing its preservation platform toward FDA clinical pathways.
Product overview
Sylvatica Biotech is a cryobanking R&D company developing a unified technology platform centered on supercooling and cryopreservation methods for organs and tissues. Their core platform enables the preservation of human livers and other organs at subzero temperatures without freezing, extending preservation time from hours to several days. The technology spans from research-grade supercooling protocols to translational applications aimed at clinical transplantation, drug discovery, and regenerative medicine. No discrete product modules or add-on offerings are named in the source material — the company's portfolio is presented as a single integrated technology capability with published scientific protocols.
Differentiator
Problem solved
Functional benefit
Products and services
- Cryobanking Technology Platform An integrated cryopreservation technology platform enabling supercooling and partial freezing of human organs (particularly livers) at subzero temperatures without ice crystal formation, extending preservation time from hours to days for transplantation, drug discovery, and regenerative medicine applications. Currently in pre-commercial R&D stage.
Quantifiable outcome
- Preservation time extended to 4 days for human livers with successful transplantation survival
- +1 more outcomes
Companies that use Sylvatica Biotech
Customer profileSegments3 records
Ideal customer profiles3 records
Sylvatica Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Sylvatica Biotech partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights5 records
Sylvatica Biotech competitors and assessment
Company assessmentDirect peers
- OrganOx: OrganOx develops the metra normothermic liver perfusion device, which preserves and assesses donor livers for transplantation. It is the most direct commercial-stage competitor to Sylvatica in liver preservation, attacking the same organ-shortage problem with a complementary (perfusion vs. supercooling) technical approach.
- TransMedics: TransMedics' Organ Care System (OCS) preserves and transports hearts, lungs, and livers using warm perfusion. It is publicly traded, FDA-approved, and directly competes with Sylvatica for transplant-center adoption of next-generation preservation technologies.
- Paragonix Technologies: Paragonix offers the SherpaPak and LazerX cold-preservation and transport systems for hearts and other organs. It competes for the same transplant-center procurement budgets and represents the static cold-storage incumbent that Sylvatica's supercooling approach aims to leapfrog.
- XVIVO Perfusion: XVIVO develops machine perfusion and preservation solutions for lungs, hearts, and other organs. It is a direct commercial-stage peer competing for transplant-center adoption of advanced preservation technology.
- Bridge to Life: Bridge to Life supplies organ preservation solutions (e.g., Belzer UW, Custodiol HTK) and cold-storage devices used widely in transplant logistics. It represents the existing static cold-storage standard that Sylvatica's subzero non-frozen approach must displace.
- Organ Recovery Systems: Organ Recovery Systems provides the LifePort kidney perfusion platform and related preservation products. It is a direct peer in machine-perfusion-based organ preservation and serves the same transplant-center customer base.
Emerging players
- Tevosol: Tevosol is developing ex-vivo organ preservation devices using machine perfusion. As a smaller, earlier-stage company targeting the same transplant preservation opportunity, it is comparable to Sylvatica in scale and stage while addressing the same unmet need with a different modality.
- 21st Century Medicine: 21st Century Medicine is a cryobiology R&D company focused on ice-free cryopreservation of organs and tissues using vitrification. It is highly comparable to Sylvatica on the underlying science (cryopreservation vs. supercooling) and is a fellow emerging player in the same translational cryobiology niche.
Broad incumbents
- United Therapeutics / Lung Bioengineering: United Therapeutics, through its Lung Bioengineering subsidiary, is developing ex-vivo lung perfusion (the XPS system) and has broader transplant and regenerative medicine programs. It is a large, well-capitalized incumbent pursuing adjacent organ-preservation applications.
Others
- Cell and Gene Therapy Catapult (cryopreservation programs): Catapult runs programs supporting cell and gene therapy manufacturing, including cryopreservation and cold-chain logistics. It is an adjacent ecosystem participant working on overlapping cryopreservation infrastructure relevant to regenerative-medicine applications of Sylvatica's technology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Sylvatica Biotech social profiles
Digital presenceSylvatica Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sylvatica Biotech leadership team
Management profileNumber of profiles
Profiles1 record
Sylvatica Biotech funding detail
Funding detailFunding overview
Funding rounds6 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sylvatica Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sylvatica Biotech
What does Sylvatica Biotech do?
Sylvatica Biotech is a cryobanking R&D company developing proprietary supercooling and partial-freezing technologies to preserve human organs (notably livers) at subzero temperatures without ice formation, extending preservation from hours to days. The technology targets transplantation, drug discovery, and regenerative medicine applications. The company is pre-commercial and focused on advancing its preservation platform toward FDA clinical pathways.
Is Sylvatica Biotech a public or private company?
Sylvatica Biotech is a private company. It is classified as venture growth investor backed and is currently operating.
When was Sylvatica Biotech founded?
Sylvatica Biotech was founded in 2015. It employs 1 to 10 people.
Where is Sylvatica Biotech based?
Sylvatica Biotech is headquartered in North Charleston, United States, in the North America region.
Who are Sylvatica Biotech's main competitors?
Direct peers on record are OrganOx, TransMedics, Paragonix Technologies, XVIVO Perfusion, Bridge to Life and Organ Recovery Systems. Emerging players are Tevosol and 21st Century Medicine. United Therapeutics / Lung Bioengineering is listed as a broad incumbent. Cell and Gene Therapy Catapult (cryopreservation programs) is listed as an others.
Does Sylvatica Biotech have an API?
No public API is recorded for Sylvatica Biotech.
What industry is Sylvatica Biotech in?
Sylvatica Biotech's product category is Organ Preservation Technology. Its primary akta.pro industry code is HLAAAJAN, Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies, with a secondary code of HLAGAIAJ, Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats). Its NAICS code is 541714 and its SIC code is 8731.